<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483674</url>
  </required_header>
  <id_info>
    <org_study_id>2020-000601-89</org_study_id>
    <nct_id>NCT04483674</nct_id>
  </id_info>
  <brief_title>Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection</brief_title>
  <acronym>BIC-PHI</acronym>
  <official_title>Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Bictegravir/FTC/TAF in patients with&#xD;
      less of 100 days post HIV infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After providing informed consent, patients will undergo to a screening visit. If they meet&#xD;
      the inclusion criteria and none of the exclusion will be included in this trial. Patients&#xD;
      will take one tablet of Biktarvy at day for 48 weeks. Then the results will be compared with&#xD;
      a cohort of 66 patients treated with 2 nucleoside analogues and one integrase chain transfer&#xD;
      inhibitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Portion of patients with a VL (viral load)&lt; 50 Copies at week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Portion of patients with rapid ART (Antiretroviral therapy) initiation who reached a VL&lt; 50 copies at 48 week in the intention to treat population determined by PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Load at 4,8,12,24 y 48 weeks</measure>
    <time_frame>weeks 4,8,12,24,48</time_frame>
    <description>Determination by PCR (Polymerase Chain Reaction) of viral load at differents weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portion of patients with &gt; 900 cells CD4+</measure>
    <time_frame>weeks 24 and 48</time_frame>
    <description>Proportion of patients with &gt;900 cells CD4+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days elapsed between diagnosis and bictegravir/FTC/TAF initiation</measure>
    <time_frame>week 48</time_frame>
    <description>Days elapsed between diagnosis and bictegravir/FTC/TAF initiation, day elapsed between first clinical visit and Bictegravir/FTC/TAF initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients treated with Bictegravir/FTC/TAF who reached a VL&lt;50 copies at 48 weeks in the intention-to-treat (ITT) population</measure>
    <time_frame>week 48</time_frame>
    <description>Proportion of patients treated with Bictegravir/FTC/TAF who reached a VL&lt;50 copies at 48 weeks in the intention-to-treat (ITT) population in comparison with other InSTI-, based ART regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE (adverse event) leading to discontinuation rate</measure>
    <time_frame>week 48</time_frame>
    <description>AE leading to discontinuation rate in comparison with other InSTI- based ATR regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4, CD4/CD8 ratio</measure>
    <time_frame>weeks 4,8,12,24,48</time_frame>
    <description>CD4, CD4/CD8 ratio at weeks 4,8,12,24 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE rate</measure>
    <time_frame>week 48</time_frame>
    <description>AE rate (overall and AE leading to discontinuation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of required regimen changes</measure>
    <time_frame>week 48</time_frame>
    <description>Number of required regimen changes stratified by: adverse events/toxicity, virological failure, simplification, transmitted drug resistance (including polymorphisms for InSTIs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and satisfaction: questionnaire</measure>
    <time_frame>day 0, week 4 and 48</time_frame>
    <description>Quality of life and satisfaction evaluated through a CESTA questionnaire (Spanish Questionnaire of Satisfaction whit Antiretroviral Treatment) at 4 and 48 weeks (or at the end of study in case of early termination) of the study period, and Pittsburgh Sleep Quality Index (PSQI) at day 0, 4 week and 48 weeks (or at the end of study in case of early termination) of the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reservoir, inflammatory and immunological markers and fecal microbiome composition</measure>
    <time_frame>weeks 0,48</time_frame>
    <description>Viral reservoir, inflammatory and immunological markers and fecal microbiome composition</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>HIV Primary Infection</condition>
  <arm_group>
    <arm_group_label>Biktarvy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one pill with 50mg bictegravir/200mg emtricitabine /25mg tenofovir alafenamide orally once a day, for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide</intervention_name>
    <description>Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:&#xD;
complete physical examination&#xD;
register concomitant medication&#xD;
blood test&#xD;
concomitant medications&#xD;
assessment od adverse events&#xD;
assessement of compliance&#xD;
PSQI and CESTA questionnaire (week 4 and 48)&#xD;
Recommendation in contraception methods&#xD;
Stool sample and pregnancy test urine (week 0 and 48)&#xD;
The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL</description>
    <arm_group_label>Biktarvy</arm_group_label>
    <other_name>Biktarvy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged 18-65 years&#xD;
&#xD;
          -  ART naïve&#xD;
&#xD;
          -  HIV infection of less than 100 days post-infection (documented 3 month previous&#xD;
             negative serology or incomplete WB test with negative p31 band)&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test in serum before&#xD;
             the inclusion in the study and agree to use highly effective contraceptive methods,&#xD;
             including intrauterine device, bilateral tubal occlusion or a vasectomized partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any drug included in Bictegravir/FTC/TAF regimen&#xD;
&#xD;
          -  AST &gt;5 times UNL&#xD;
&#xD;
          -  Creatinine Clearance &lt;30 mL/min/1.73m2&#xD;
&#xD;
          -  Any end-stage organ disease&#xD;
&#xD;
          -  Acute or chronic HCV co-infection&#xD;
&#xD;
          -  Use of PrEP with Truvada® until 4 weeks before the onset of symptoms of PHI (risk of&#xD;
             acquired-drug resistance to FCT or TDF).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Cruceta, MD</last_name>
    <phone>9322754000</phone>
    <phone_ext>4380</phone_ext>
    <email>acruceta@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose María Miró, MD</last_name>
    <email>jmmiro@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose M Miró, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Ambrosioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Mallolas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonsoles Sanchez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Montserrat Plana</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Rovira</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Hurtado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Alcamí</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>HIV Primary Infection</keyword>
  <keyword>Biktarvy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

